Sulfonylurea use and the risk of hospital readmission in patients with type 2 diabetes

被引：0
|
作者：
Pamela C. Heaton
Vibha C. A. Desai
Christina M. L. Kelton
Swapnil N. Rajpathak
机构：
[1] University of Cincinnati Academic Health Center,Pharmacy Practice and Administrative Sciences, James L. Winkle College of Pharmacy
[2] HealthCore,Carl H. Lindner College of Business
[3] University of Cincinnati,undefined
[4] US Outcomes Research,undefined
[5] Merck & Co.,undefined
[6] Inc.,undefined
来源：
BMC Endocrine Disorders | / 16卷
关键词：
Sulfonylureas; Oral antihyperglycemic agents; Type 2 diabetes; Hospital readmissions;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Sulfonylurea treatment in type 2 diabetes
    Bester, Kirstin
    Ton, Joey
    Korownyk, Christina
    CANADIAN FAMILY PHYSICIAN, 2018, 64 (04) : 295 - 295
  • [32] EMPAGLIFLOZIN USE AND THE RISK OF NEPHROLITHIASIS IN PATIENTS WITH TYPE 2 DIABETES
    Tang, Francesca
    Paik, Julie
    Tesfaye, Helen
    Zakoul, Heidi
    Schmedt, Niklas
    Koeneman, Lisette
    Seman, Leo
    Curhan, Gary C.
    Wexler, Deborah J.
    Patorno, Elisabetta
    NEPHROLOGY, 2023, 28 : 29 - 29
  • [33] Empagliflozin Use and the Risk of Nephrolithiasis in Patients With Type 2 Diabetes
    Paik, Julie M.
    Tesfaye, Helen
    Zakoul, Heidi
    Schmedt, Niklas
    Koeneman, Lisette
    Seman, Leo
    Curhan, Gary C.
    Wexler, Deborah J.
    Patorno, Elisabetta
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 673 - 673
  • [34] Utility of the Hospital Admission Risk Programme diabetes risk calculator in identifying patients with type 2 diabetes at risk of unplanned hospital presentations
    McGrath, Rachel T.
    Dryden, Justin C.
    Newlyn, Neroli
    Pamplona, Elline
    O'Dea, Judy
    Hocking, Samantha L.
    Glastras, Sarah J.
    Fulcher, Gregory R.
    INTERNAL MEDICINE JOURNAL, 2018, 48 (10) : 1198 - 1205
  • [35] Sulfonylurea are associated with a higher adjusted risk of myocardial infarction compared to metformin in patients with type 2 diabetes
    Pilon, D
    Beaudette, CP
    Maheux, P
    DIABETES, 2004, 53 : A252 - A252
  • [36] Sulfonylurea and Cancer Risk Among Patients With Type 2 Diabetes: A Population-Based Cohort Study
    Zhao, Houyu
    Liu, Zhike
    Zhuo, Lin
    Shen, Peng
    Lin, Hongbo
    Sun, Yexiang
    Zhan, Siyan
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [37] Sulfonylurea Use in Patients with Type 2 Diabetes and COPD: A Nationwide Population-Based Cohort Study
    Yen, Fu-Shun
    Wei, James Cheng-Chung
    Yu, Teng-Shun
    Hsu, Chung Y.
    Hsu, Chih-Cheng
    Hwu, Chii-Min
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (22)
  • [38] The futile cycle of hospital readmission in patients with diabetes
    Swami, Janya
    Korytkowski, Mary
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2017, 31 (08) : 1252 - 1253
  • [39] Sulfonylurea Use Associated with Higher Emergency Room Utilization among Elderly Patients with Type 2 Diabetes
    Rajpathak, Swapnil
    Fu, Chunmay
    Brodovicz, Kimberly
    Engel, Samuel
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 488 - 488
  • [40] Genetic risk factors for type 2 diabetes mellitus and response to sulfonylurea treatment
    Swen, Jesse J.
    Guchelaar, Henk-Jan
    Baak-Pablo, Renee F.
    Assendelft, Willem J. J.
    Wessels, Judith A. M.
    PHARMACOGENETICS AND GENOMICS, 2011, 21 (08): : 461 - 468
12345